文献速递冠心病

EXCROSSAL支架治疗原发冠脉病变5年临床结局

[Five-year clinical outcomes of the second generation biodegradable polymer sirolimus-eluting stent (EXCROSSAL) in treating patients with de novo coronary lesions].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2021-01-01

本研究纳入CREDIT Ⅱ和CREDIT Ⅲ研究中置入EXCROSSAL支架的833例原发原位冠状动脉病变冠心病患者,随访5年。结果显示TLF发生率为10.6%、PoCE为15.5%、支架内血栓为1.0%,提示该支架长期有效安全。

要点

  • EXCROSSAL支架5年TLF发生率10.6%,PoCE发生率15.5%,支架内血栓1.0%。
  • 小血管病变、长病变和多支病变是5年TLF的相关因素。
  • 该支架治疗原发原位冠脉病变长期有效性与安全性较好。

核心结论

  • EXCROSSAL支架治疗原发原位冠状动脉病变5年TLF和PoCE发生率均较低,长期有效性与安全性较好。

研究设计与样本

  • 研究纳入CREDIT Ⅱ随机对照研究和CREDIT Ⅲ单臂研究中置入EXCROSSAL支架的冠心病患者。
  • 2013年11月至2014年12月全国33个中心共入选833例原发原位冠状动脉病变患者,年龄(59.3±9.1)岁,男性579例(69.5%)。
  • 主要终点为5年TLF,次要终点为PoCE和ARC定义支架内血栓,采用Kaplan-Meier法计算发生率,单因素Cox回归分析相关因素。

主要发现

  • 5年TLF发生率为10.6%(86/811),PoCE发生率为15.5%(126/811),支架内血栓发生率为1.0%(8/811)。
  • 血管直径≤2.74 mm(HR=3.20,95%CI 1.90~5.39,P<0.001)是5年TLF的相关因素。
  • 病变长度≥16.7 mm(HR=1.88,95%CI 1.18~2.99,P=0.007)是5年TLF的相关因素。
  • 多支病变(HR=2.44,95%CI 1.60~3.72,P<0.001)是5年TLF的相关因素。

临床怎么用

  • EXCROSSAL支架可用于原发原位冠状动脉病变的冠心病患者,5年TLF和PoCE发生率较低。
  • 对合并小血管病变、长病变或多支病变的患者,应关注5年TLF风险。

局限性

  • CREDIT Ⅲ为单臂研究,CREDIT Ⅱ为随机对照研究,合并分析时需考虑设计差异。
  • 原文未报告多因素校正分析,相关因素仅来自单因素Cox回归。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the five-year safety and efficacy of the second generation biodegradable polymer sirolimus-eluting stent (EXCROSSAL) in treating patients with de novo coronary artery diseases. Methods: Patients with coronary artery disease (CAD)who were implanted with EXTROSSAL stents in CREDIT Ⅱ and CREDIT Ⅲ study were included. CREDIT Ⅱ was a randomized trial, and CREDIT Ⅲ was a single-arm study. From November 2013 to December 2014, 833 CAD patients with de novo coronary lesions implanted with EXTROSSAL stents were selected from 33 centers in China. The primary outcome was 5-year target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction and clinically indicated target lesion revascularization. Secondary endpoints was patient-oriented composite endpoint (PoCE), including all-cause death, all myocardial infarction, or any revascularization within 5 years post stenting and stent thrombosis according to Academic Research Consortium's (ARC) definition. Kaplan Meier method was used to calculate the incidence of TLF and PoCE within 5 years after operation. Univariate Cox regression analysis was used to analyze the impacts of diabetes, small vessel disease (vessel diameter ≤ 2.74 mm), lesion length ≥ 16.7 mm and multivessel disease on the incidence of TLF within 5 years after operation. Results: A total of 833 patients were included in this study including 579 males (69.5%), the age was (59.3±9.1) years. And 832 (99.9%) patients completed 5-year clinical follow-up. The incidence of TLF and PoCE in the 5-year follow-up were 10.6%(86/811) and 15.5%(126/811), respectively. Stent thrombosis occurred in 1.0%(8/811) of patients. Univariate Cox regression analysis showed that vessel diameter ≤ 2.74 mm (HR=3.20,95%CI 1.90-5.39,P<0.001), lesion length ≥ 16.7 mm (HR=1.88,95%CI 1.18-2.99,P=0.007) and multivessel disease (HR=2.44,95%CI 1.60-3.72,P<0.001) were related factors of TLF within 5 years after operation. Conclusion: EXCROSSAL stent is effective and safe in treating CAD patients with de novo coronary lesions, with low incidence of TLF and PoCE within 5 years after operation. 目的: 评价第二代生物可降解涂层钴铬合金西罗莫司洗脱支架EXCROSSAL治疗原发原位冠状动脉病变的长期安全性和有效性。 方法: 本研究纳入CREDIT Ⅱ研究和CREDIT Ⅲ研究中置入EXCROSSAL支架的冠心病患者,CREDIT Ⅱ研究是一项随机对照研究,CREDIT Ⅲ研究是一项单臂研究。本研究从2013年11月至2014年12月于全国33个中心共成功入选置入EXCROSSAL支架的原发原位冠状动脉病变患者833例。主要终点为支架置入后5年靶病变失败(TLF),即心原性死亡、靶血管心肌梗死和临床症状驱动的靶病变血运重建组成的复合终点;次要终点为支架置入后5年患者相关的心血管复合终点(PoCE,包含全因死亡、所有心肌梗死及任何临床症状驱动的血运重建组成的复合终点)和依据美国学术研究联合会定义的支架内血栓。采用Kaplan-Meier法计算术后5年TLF及PoCE发生率。采用单因素Cox回归分析糖尿病、小血管病变(血管直径≤2.74 mm)、病变长度≥16.7 mm和多支病变对术后5年TLF发生情况的影响。 结果: 共纳入833例置入EXCROSSAL支架的冠心病患者,年龄为(59.3±9.1)岁,其中男性579例(69.5%)。811例(97.4%)患者完成了5年随访。EXCROSSAL支架置入5年TLF发生率为10.6%(86/811),PoCE发生率为15.5%(126/811),支架内血栓发生率为1.0%(8/811)。单因素Cox回归分析结果显示血管直径≤2.74 mm(HR=3.20,95%CI 1.90~5.39,P<0.001),病变长度≥16.7 mm(HR=1.88,95%CI 1.18~2.99,P=0.007)和多支病变(HR=2.44,95%CI 1.60~3.72,P<0.001)是术后5年TLF的相关因素。 结论: EXCROSSAL支架治疗原发原位冠状动脉病变的长期有效性与安全性较好,术后5年TLF及PoCE的发生率均较低。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang G, Na K, Li Y, et al. [Five-year clinical outcomes of the second generation biodegradable polymer sirolimus-eluting stent (EXCROSSAL) in treating patients with de novo coronary lesions]. Zhonghua Xin Xue Guan Bing Za Zhi. 2021. PMID: 33611897. doi:10.3760/cma.j.cn112148-20200916-00740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。